US Stock MarketDetailed Quotes
VRCA Verrica Pharmaceuticals
- 2.800
- -0.110-3.78%
Close Aug 16 16:00 ET
- 2.790
- -0.010-0.36%
Post 17:31 ET
119.47MMarket Cap-1481P/E (TTM)
2.890High2.700Low1.35MVolume2.890Open2.910Pre Close3.74MTurnover8.94%Turnover RatioLossP/E (Static)42.67MShares11.41052wk High-8.97P/B42.30MFloat Cap2.70052wk Low--Dividend TTM15.11MShs Float23.290Historical High--Div YieldTTM6.53%Amplitude1.770Historical Low2.772Avg Price1Lot Size
Verrica Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -250.35%-16.36M | -334.58%-19.95M | -106.85%-38.58M | -192.83%-14.51M | -911.56%-14.81M | 34.98%-4.67M | 44.96%-4.59M | 32.38%-18.65M | 43.04%-4.95M | 117.22%1.83M |
| Net income from continuing operations | -56.38%-17.19M | -208.56%-20.33M | -173.59%-67M | -314.94%-24.61M | -29,981.93%-24.8M | -8.08%-10.99M | 22.21%-6.59M | 30.20%-24.49M | 37.82%-5.93M | 100.65%83K |
| Operating gains losses | ---- | ---- | 76.55%2.54M | --2.48M | ---- | ---- | ---- | --1.44M | --0 | 2,201.75%1.31M |
| Depreciation and amortization | 61.35%334K | 68.32%340K | 16.43%836K | 7.96%217K | -34.58%210K | 111.22%207K | 106.12%202K | 52.12%718K | -45.68%201K | 494.44%321K |
| Other non cash items | --516K | --483K | 108.23%810K | 4,190.91%472K | ---- | ---- | ---- | -73.02%389K | -96.95%11K | -170.45%-248K |
| Change In working capital | -152.32%-2.39M | -457.18%-2.51M | 647.72%9.86M | 1,269.95%4.87M | 73.91%-281K | 229.73%4.57M | 141.52%703K | -236.45%-1.8M | 61.90%-416K | -534.27%-1.08M |
| -Change in receivables | -2,135.04%-2.62M | -837.12%-3.18M | -706.78%-3.93M | -405.88%-344K | -1,839.80%-3.9M | -154.93%-117K | 200.00%431K | ---487K | ---68K | ---201K |
| -Change in prepaid assets | -120.74%-337K | -200.71%-1.28M | 228.73%587K | 41.67%-420K | -140.31%-1.88M | 218.00%1.63M | 135.75%1.27M | 16.02%-456K | -132.26%-720K | -73.84%-784K |
| -Change in payables and accrued expense | -79.59%640K | 319.57%2.02M | 2,375.21%13.49M | 1,189.14%5.7M | 23,345.83%5.58M | 330.63%3.14M | 47.10%-920K | -184.11%-593K | 160.97%442K | -103.17%-24K |
| -Change in other current liabilities | -8.22%-79K | -6.76%-79K | -10.23%-291K | 4.29%-67K | -13.24%-77K | -10.61%-73K | -23.33%-74K | -34.01%-264K | -22.81%-70K | -19.30%-68K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -250.35%-16.36M | -334.58%-19.95M | -106.85%-38.58M | -192.83%-14.51M | -911.56%-14.81M | 34.98%-4.67M | 44.96%-4.59M | 32.38%-18.65M | 43.04%-4.95M | 117.22%1.83M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 81.36%-11K | 0 | -100.67%-362K | -103.36%-227K | -103.14%-65K | -102.68%-59K | -100.03%-11K | 5,514.93%54.04M | 68.39%6.75M | -67.11%2.07M |
| Net PPE purchase and sale | 81.36%-11K | --0 | -19.87%-362K | -243.94%-227K | 15.58%-65K | 61.69%-59K | -120.00%-11K | 65.80%-302K | 72.15%-66K | -97.44%-77K |
| Net investment purchase and sale | ---- | ---- | --0 | --0 | ---- | ---- | ---- | 63,089.53%54.34M | 55.99%6.82M | -68.40%2M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 81.36%-11K | --0 | -100.67%-362K | -103.36%-227K | -103.14%-65K | -102.68%-59K | -100.03%-11K | 5,514.93%54.04M | 68.39%6.75M | -67.11%2.07M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -661.90%-640K | -102.18%-661K | 539.91%74.21M | -28K | 361.37%44.04M | -8,300.00%-84K | 168,322.22%30.28M | -150.14%-16.87M | 0 | -39,288.37%-16.85M |
| Net issuance payments of debt | --332K | ---665K | 200.75%44.08M | ---23K | 200.81%44.11M | --0 | --0 | -980.36%-43.75M | --0 | -2,187,500.00%-43.75M |
| Net common stock issuance | --0 | --0 | 12.64%30.3M | ---1K | --0 | --0 | --30.3M | -4.33%26.9M | --0 | --26.9M |
| Proceeds from stock option exercised by employees | --150K | -42.86%4K | --7K | --0 | --0 | --0 | --7K | --0 | --0 | --0 |
| Net other financing activities | ---- | ---- | -935.29%-176K | ---3K | ---61K | ---84K | -64.71%-28K | ---17K | --0 | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -661.90%-640K | -102.18%-661K | 539.91%74.21M | ---27K | 361.37%44.04M | -8,300.00%-84K | 168,322.22%30.28M | -150.14%-16.87M | --0 | -39,288.37%-16.85M |
| Net cash flow | ||||||||||
| Beginning cash position | -18.37%48.94M | 102.92%69.55M | 117.58%34.27M | 159.62%84.31M | 21.37%55.14M | 18.94%59.95M | 117.58%34.27M | 47.41%15.75M | 58.85%32.47M | 83.88%45.43M |
| Current changes in cash | -253.47%-17.01M | -180.25%-20.61M | 90.45%35.27M | -920.06%-14.76M | 325.11%29.17M | 3.32%-4.81M | -25.90%25.68M | 265.59%18.52M | 138.38%1.8M | -203.87%-12.96M |
| End cash Position | -42.09%31.93M | -18.37%48.94M | 102.92%69.55M | 102.92%69.55M | 159.62%84.31M | 21.37%55.14M | 18.94%59.95M | 117.58%34.27M | 117.58%34.27M | 58.85%32.47M |
| Free cash flow | -246.21%-16.37M | -333.54%-19.95M | -105.46%-38.94M | -193.51%-14.73M | -951.03%-14.88M | 35.54%-4.73M | 44.87%-4.6M | 33.42%-18.95M | 43.82%-5.02M | 116.43%1.75M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg